



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, Mail Stop DD, PO Box 1450,
Alexandria, VA 22313 on October 15, 2003.

David Saliwanchik

David R. Saliwanchik, Patent Attorney

INFORMATION DISCLOSURE
STATEMENT

Patent Application
Docket No. ALL-T101D1
Serial No. 10/643,298

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Ann de Wees Allen
Serial No. : 10/643,298
Filed : August 18, 2003
For : A Composition Comprising L-Arginine as a Muscle Growth Stimulant and Use Thereof

Commissioner for Patents
Mail Stop DD
P.O. Box 1450
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.97 and §1.98(d), the applicant would like to bring to the attention of the Examiner, the references cited in the following patent application:


U.S. Serial No. 08/938,801, filed September 26, 1997 (now U.S. Patent No. 6,608,109).

The subject application, Serial No. 10/643,298 claims the benefit under 35 USC §120 of the filing date of the above application. The applicant respectfully request that the copies of references supplied in the Information Disclosure Statement of the above-mentioned application (U.S. Serial No. 08/938,801) be made of record in the 10/643,298 application. As copies of all of the references

filed in the parent application, and cited on the attached form PTO/SB/08, will be found in the parent casefile, copies of those references are not provided herewith.

The applicant respectfully asserts that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.


Respectfully submitted,



David R. Saliwanchik
Patent Attorney
Registration No. 31,794
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address : 2421 N.W. 41st Street, Suite A-1
Gainesville, Florida 32606-6669

DRS/tl

Attachment: Form PTO/SB/0



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/643,298	
			Filing Date	August 18, 2003	
			First Named Inventor	Ann de Wees Allen	
			Art Unit	Not yet assigned	
			Examiner Name	Not yet assigned	
Sheet	1	of	1	Attorney Docket Number	ALL-T101D1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US- 4,604,286	08-1986	Kawajiri	All
	U2	US- 4,734,401	03-1988	Blouin	All
	U3	US- 5,026,721	06-1991	Dudrick <i>et al.</i>	All
	U4	US- 5,087,624	02-1992	Boyton <i>et al.</i>	All
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			
	U12	US-			
	U13	US-			
	U14	US-			
	U15	US-			
	U16	US-			
	U17	US-			
	U18	US-			
	U19	US-			
	U20	US-			


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	AU 4068972	10-1973	Muhammed <i>et al.</i>		
	F2	FR 2547501	12-1984	Donzeau		
	F3					
	F4					
	F5					
	F6					
	F7					
	F8					
	F9					
	F10					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/643,298
				Filing Date	August 18, 2003
				First Named Inventor	Ann de Wees Allen
				Group Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
				Attorney Docket Number	ALL-T101D1
Sheet	2	of	2		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	SALOMON, FRANCO <i>et al.</i> "The Effects of Treatment with . . ." <i>Growth Hormone Treatment in Adults</i> , Vol. 321, No. 26, pp. 1797-1803.	
	R2	VANCE, "Growth Hormone for the Elderly" <i>The New England Journal of Medicine</i> 1990, Vol. 321, No. 1, pp. 52-54.	
	R3	RUDMAN <i>et al.</i> "Growth Hormone Treatment of Frailty in Men Over 60" <i>New England Journal of Medicine</i> 1990, pp. 1-9.	
	R4	COLGAN, "Fitness and Aging" <i>Muscular Development</i> , pp. 138-140 and 126-128.	
	R5	MARTINDALE, <i>The Extra Pharmacopoeia</i> , 28 th Edition (1982), p. 49.	
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+